It was about a year ago that I highlighted here some neat graphene technology out of Cardea Biosciences, and in that context I mentioned CRISPR-based diagnostics. (If interested, you can find the post here.) The FDA recently approved under Emergency Use Authorization (EUA) Sherlock BioSciences’ SARS-CoV-2 Rapid diagnostic (FDA EUA page is here) and let’s … Read more
One of the first serosurvey results from Santa Clara county in California reports 48,000 to 81,000 people infected, 50-fold to 85-fold more than the number of confirmed cases. Living through a pandemic while under lockdown order, with schools and routines and social events and music concerts and movie theaters and sports events all closed means … Read more
Using both traditional blood draw and an innovative home-collection device, the NIH recruits 1000 healthy volunteers nationwide The SARS-CoV-2 virus (otherwise known as coronavirus, the causative virus of COVID-19 disease currently rampaging worldwide) is a difficult pathogen to battle. While clearing out my bursting-at-the-seams ‘downloads’ folder on my computer this morning, I came across two … Read more
First preliminary results from widespread IgA/IgG SARS-CoV-2 resistance antibody testing in Heinsberg Germany Being an active research scientist or having a life science research background during a once-in-a-lifetime worldwide epidemic is a remarkable thing. Whether reading pre-prints on MedRxiv or looking into the latest news of the day or reading interesting links from a variety … Read more
The US FDA clears the first serology test for assessing infectious spread In many ways it is difficult to assess the passage of time while in a national shutdown. It was a little over a week ago that I wrote about the need for a good antibody test for SARS-CoV-2, in order to get decent … Read more
John Iafrede (Massachusetts General Hospital, MA) “There is a tidal wave of cell-free approaches; little performance testing; and the big question is who is going to pay for it.” This year’s Assocation for Molecular Pathology was held in Salt Lake City, Utah from November 15-18, 2017. (You can find the 2017 program and abstract here.) … Read more
Every mother-to-be who has what is considered an ‘at-risk’ pregnancy is informed of the risks to the fetus of a genetic abnormality. ‘At-risk’ can involve a long list of medical conditions (diabetes or cancer for example) or poor health choices (illegal drug use or smoking). Yet a common cause of an at-risk pregnancy is age, having a child before the age of 17 or older than 35. In the US, no less than 750,000 are considered at-risk.